Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer Clinical Trial

— ENCORE  

Official title:

A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined With Other Agents in Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04754191
• Other study ID #: HCI137651
• Status: Recruiting
• Phase: Phase 2
• Start date: February 3, 2022
• Est. completion date: September 2026

Study information

• Verified date: June 2023
• Source: University of Utah
• Contact: Susan Sharry
• Phone: 801-585-3453
• Email: susan.sharry[@]hci.utah.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, phase II umbrella trial assessing the anti-tumor activity of enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic castration-resistant prostate cancer. The trial will open to enrollment in Cohort A, enfortumab monotherapy. Additional cohorts may be added as new drug combinations are identified.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 34
• Est. completion date: September 2026
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male subject aged = 18 years.
• Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology.
• Diagnosis of metastatic or locally advanced, inoperable disease that cannot be treated with definitive intent
• Castrate levels of testosterone as defined as < 50 ng/dL (1.73 nmol/L).
• Prior treatment with at least three or more cycles of docetaxel therapy. Note:

Docetaxel in the newly diagnosed metastatic setting and docetaxel rechallenge allowed.

• Prior treatment with at least one prior Novel Hormone Therapy (NHT), defined as second-generation antiandrogen therapies that include but are not limited to abiraterone acetate, enzalutamide, apalutamide, and darolutamide.
• Subject has received or refused therapies other than cabazitaxel which have shown to improve overall survival and are recommended per NCCN guidelines prior to enrollment in trial. Such agents include but are not limited to sipuleucel-T, olaparib, rucaparib, radium-223 and lutetium (177Lu) vipivotide tetraxetan depending on patient eligibility.
• Had disease progression on or after NHT prior to enrolling in the study.
• ECOG Performance Status = 2.
• Adequate organ function as defined as:
• Hematologic:
• White blood cell count (WBC) = 2000/mm3
• Absolute neutrophil count (ANC) = 1500/mm3
• Platelet count = 100,000/mm3
• Hemoglobin = 9g/dL
• Hepatic:
• Total Bilirubin = 1.5x institutional upper limit of normal (ULN) unless there is a known history of Gilbert's syndrome.
• AST(SGOT)/ALT(SGPT) = 5 × institutional ULN
• Renal:
• Estimated creatinine clearance = 30 mL/min by Cockcroft-Gault formula:
• Highly effective contraception throughout the study as described in Section 7.4.
• Discontinued all previous treatments for cancer (except androgen-deprivation therapy and bone loss prevention treatment) 28 days prior to starting study therapy.
• Recovery to baseline or = Grade 1 CTCAE v 5.0 from toxicities related to any prior treatments, unless AE(s) are clinically non-significant and/or stable on supportive therapy as determined by the treating physician.
• Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

• Prior or concurrent malignancy (other than adenocarcinoma of the prostate). Note:

Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial as approved by the Principal Investigator.

• The subject has an uncontrolled, significant intercurrent or recent illness that would preclude safe study participation.
• Clinically significant cardiovascular disease: myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (> New York Heart Association Classification Class IIB) or a serious cardiac arrhythmia requiring medication.
• Known HIV infection with a detectable viral load at the time of screening. Note:

Patients on effective antiretroviral therapy with an undetectable viral load at the time of screening are eligible for this trial.

• Known chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection with a detectable viral load. Note: Patients with an undetectable HBV viral load are eligible. Patients with an undetectable HCV viral load are eligible.
• Live attenuated vaccinations within = 4 weeks of the first study therapy and while on trial is prohibited.
• Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v5.0 Grade = 3).
• Subjects taking prohibited medications as described in Section 6.3. A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur prior to the start of treatment.

Related Conditions & MeSH terms

• Metastatic Castration-resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Enfortumab vedotin
Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.

Locations

Country	Name	City	State
United States	Huntsman Cancer Institute	Salt Lake City	Utah

Sponsors (2)

Lead Sponsor	Collaborator
University of Utah	Astellas Pharma Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion subjects achieving one of the following: Objective response by RECIST1.1, Confirmed conversion of circulating tumor cell count (CTC) to <5/7.5 mL blood, PSA decline = 50% from baseline, or Stable disease = 6 months per PCWG3 mod.RECIST 1.1	assess the anti-tumor action of the study therapy in subjects with metastatic castrate-resistant prostate cancer	12 months